Clinical trials: Hepatocellular Cancer, open to volunteers
Hepatocarcinoma
Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
This is a prospective, single-center, phase II study，to evaluate the efficacy and safety of icariin soft capsules combined with TACE as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after…
- Trial name
- NCT06900478
- Testing
- Icariin Soft Capsules+TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hua Li
Primary Liver Cancer
Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
A phase II clinical trial of stereotactic radiosurgery versus radiofrequency ablation in the treatment of inoperable primary liver cancer in specific sites
- Trial name
- NCT06766643
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Radiofrequency ablation therapy
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hemostasis in Decompensated Liver Cirrhosis, Inflammation in Decompensated Liver Cirrhosis
Hemostasis in Liver Cirrhosis and Hepatocellular Cancer
Evaluating hemostasis in decompensated liver cirrhosis with novel hemostatic assays.
- Trial name
- HELICS (NCT06212635)
- Testing
- T-TAS
- Where
- Sweden
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Region Stockholm
HCC - Hepatocellular Carcinoma, Colorectal Cancer Metastatic
ctDNA Monitoring in Patients With HCC and mCRC
"Liquid biopsy" is a collective term that refers to the analysis of cancer-derived biomarkers isolated from the biological fluids of cancer patients.
- Trial name
- NCT07001085
- Testing
- Tumor Tissue Collection and NGS, Blood Collection for Plasma ctDNA, ctDNA Mutation Analysis via ddPCR
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Medical University of Warsaw
Mixed Hepatocellular-cholangiocarcinoma
HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)
To evaluate HAIC combined with Camrelizumab plus rivoceranib for advanced mixed hepatocellular-cholangiocarcinoma (HCC-CCA).
- Trial name
- TASK-05 (NCT07105748)
- Testing
- Camrelizumab, Rivoceranib (Apatinib), HAIC
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Colorectal Neoplasms, Neoplasm Metastases
Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)
Eligible patients with high risk colorectal malignancy (T3/4, spread greater than 5mm, EMVI positive) will have additional surveillance of breath hold T1, T2 and DW-MRIs (no IV contrast) post surgery six monthly for three years.
- Conditions
- Colorectal Neoplasms, Neoplasm Metastases, Hepatic Neoplasms
- Trial name
- SERENADE (NCT02246634)
- Testing
- Diffusion Weighted MRI scan
- Where
- 13 sites in United Kingdom
- Volunteers
- 282 people
- Sponsor
- Imperial College London
Hepatocellular Carcinoma (HCC)
Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
In this study, we explored and validated the predictive value of the longitudinal monitoring model of urinary proteomics for postoperative recurrence of hepatocellular carcinoma and the predictive value of minimal residual…
- Trial name
- NCT06861114
- Testing
- Urine proteomics
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Zhujiang Hospital
Liver Diseases, Humans
Liver Disease and Other Systemic Diseases
Examine the association of chronic liver diseases (including hepatitis B, hepatitis C, alcoholic liver disease, fatty liver, liver cirrhosis, and hepatocellular carcinoma) with other systemic diseases by retrospectively analyzing…
- Conditions
- Liver Diseases, Humans, Progression, Carcinogenesis
- Trial name
- NCT04525833
- Where
- Taiwan
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Immunotherapy, HCC - Hepatocellular Carcinoma
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
The interventional, randomized, placebo-controlled, double-blind phase II-trial FLORA will assess safety and immunogenicity of fecal microbiota transfer in combination with standard of care immunotherapy in advanced…
- Trial name
- FLORA (NCT05690048)
- Testing
- Fecal microbiota transfer, Vancomycin Oral Capsule, Atezolizumab + Bevacizumab
- Where
- 7 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Michael Dill
Solid Tumor Cancer, Neoplasms
AI-Driven Tumor Response Evaluation for Solid Tumors
Purpose: This study is developing and validating an artificial intelligence (AI)-driven system to evaluate tumor response using changes in total tumor volume.
- Conditions
- Solid Tumor Cancer, Neoplasms, Hepatocellular Carcinoma
- Trial name
- NCT07685548
- Testing
- Observational Data Collection
- Volunteers
- 6,120 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Cancer, Cancer, Treatment-Related
Unravelling the Impact of Radiofrecuency in Liver Surgery: the Key to Decrease Local Recurrence?
Radiofrequency devices have been increasingly employed in liver surgery in order to achieve proper hemostasis and this use has become more evident with the implementation of minimal invasive surgery.
- Trial name
- LIVERaTION (NCT05492136)
- Testing
- Additional margin coagulation
- Where
- Spain
- Volunteers
- 720 people
- Sponsor
- Hospital del Mar
Liver Tumors
Safety and Clinical Efficacy of Histotripsy for Liver Cancers Adjacent to Major Intrahepatic Vessels
Malignant liver tumors are among the most common malignancies worldwide, with over 10,000 new cases diagnosed annually in Taiwan.
- Trial name
- NCT07063771
- Testing
- Histotripsy
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Head and Neck Cancers, Breast Cancer
Feasibility Study of CBCT for IGRT in Cancer Patients
Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy…
- Conditions
- Head and Neck Cancers, Breast Cancer, Thoracic Cancers, Liver Cancer
- Trial name
- NCT06681233
- Testing
- Comparison of HyperSight CBCT imaging to conventional CBCT imaging.
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Varian, a Siemens Healthineers Company
Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced…
- Conditions
- Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
- Trial name
- NCT05984511
- Testing
- I-125 Seeds Brachytherapy in PVTT, Transcatheter arterial chemoembolization, Atezolizumab plus Bevacizumab
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatocellular Carcinoma, Beyond Milan Criteria
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
Surgical resection is the primary curative treatment for patients with hepatocellular carcinoma (HCC), with a 5-year overall survival rate of 60-80% post-surgery.
- Trial name
- NCT06467799
- Testing
- Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
HCC, Hepatocellular Carcinoma
Y-90 Treatment Response Using Transarterial Radioembolization
This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE).
- Conditions
- HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm
- Trial name
- TARE (NCT07145801)
- Testing
- Lumason, Sonazoid
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Jefferson University
Hepatocellular Carcinoma
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with…
- Trial name
- NCT05620771
- Testing
- Y90 + Atezolizumab and Bevacizumab, Y90 + TKI
- Where
- 7 sites in United States
- Volunteers
- 200 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma (HCC)
Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome
The goal of this interventional study (clinical trial) is to evaluate the efficacy and safety of adding dapagliflozin to first-line standard therapy in patients with unresectable hepatocellular carcinoma (HCC) and comorbid…
- Trial name
- NCT07729592
- Testing
- Dapagliflozin, Donafenib, Tislelizumab
- Volunteers
- 44 people
- Sponsor
- Sun Yat-sen University
HCC - Hepatocellular Carcinoma, Conversion Therapy
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
Conversion therapy for unresectable intermediate-advanced hepatocellular carcinoma (uHCC) has evolved from systemic therapy to combined local-systemic approaches, but current regimens still have limited surgical conversion rates.
- Trial name
- NCT07560488
- Testing
- Bevacizumab Biosimilar IBI305, ipilimumab N01, Sintilimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Solid Tumor, Gastric Cancer
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SON-DP in Subjects with Advanced Solid Tumors
- Conditions
- Solid Tumor, Gastric Cancer, Liver Cancer
- Trial name
- NCT06873659
- Testing
- SON-DP
- Where
- 11 sites in China
- Volunteers
- 96 people
- Sponsor
- Qurgen Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.